Biostem Technologies (BSEM) Company presentation summary

Mission and vision

• Focused on delivering advanced wound healing technologies to improve patient outcomes.

• Committed to innovation in regenerative medicine, particularly perinatal tissue allografts.

Market opportunity and growth strategy

• Targets a $23B US soft tissue allograft market across orthopedics, wound care, spine, urology, and women’s health.

• Expanding into hospital settings and new patient populations to diversify revenue and payer coverage.

• Growth driven by acquisitions, new product launches, and expanding the commercial team.

Product portfolio and technology

• Offers six perinatal-derived allograft brands, including newly acquired Neox and Clarix families.

• Proprietary platforms: BioRetain, CryoTek, and SteriTek, preserving natural tissue properties for healing.

• Pipeline includes a 510(k) clearance submission for a Flo-based product.